Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cozaar · 1 trial · 1 indication
Peak Plasma Concentration (Cmax)
| Arm | Type | Description |
|---|---|---|
| Losartan potassium 100 mg Tablets | EXPERIMENTAL | Losartan potassium is the test product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Losartan potassium. |
| Cozaar® (Losartan potassium)100 mg Tablets | ACTIVE_COMPARATOR | Cozaar® (Losartan potassium) is the reference product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Cozaar®. |
| Name | Type | Description |
|---|---|---|
| Cozaar 100mg Tablet | DRUG | Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe \& Dohme B.V. , Haarlem, the Netherlands) |
| Losartan potassium 100mg | DRUG | Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus) |
Inclusion Criteria: The following criteria should be checked at the time of study entry. If any does not apply at the time of study entry, the subject must not be included in the study: 1. Healthy adult human subjects, aged between 18 to 45 years (both inclusive). 2. Subjects with Body Mass Index ...
Cozaar is a small molecule drug being developed by Ligand Pharmaceuticals Incorporated (ticker: LGND). It is currently in Phase 1 clinical development. The drug is being studied for use in healthy individuals, and its therapeutic area is classified as Other.
Cozaar is being studied for use in healthy individuals. It is currently in Phase 1 clinical development. The drug is not approved for any specific disease or condition, and its therapeutic area is classified as Other.
Cozaar is being developed by Ligand Pharmaceuticals Incorporated, which trades under the ticker symbol LGND. The company is conducting clinical trials to evaluate the drug in healthy volunteers.
Cozaar is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess its safety and pharmacokinetics.
Cozaar has one completed Phase 1 clinical trial, identified as NCT03459911. This trial was a bioequivalence study of losartan potassium tablets (100 mg) in healthy adults under fasting conditions. The study was conducted in India with 66 participants.
Cozaar is being studied as losartan potassium tablets. The clinical trial NCT03459911 evaluated losartan potassium 100 mg tablets. The drug is being developed by Ligand Pharmaceuticals Incorporated under the name Cozaar.